Phase-II trial of 1,2-diaminocyclohexane (4-carboxyphthalato) platinum (II) (DACCP) in non-small cell lung cancer

@article{Scher1984PhaseIITO,
  title={Phase-II trial of 1,2-diaminocyclohexane (4-carboxyphthalato) platinum (II) (DACCP) in non-small cell lung cancer},
  author={Howard I. Scher and David K Kelsen and Leonard Kalman and Larry Jones and Joseph Burchenal and Richard J. Gralla},
  journal={Cancer Chemotherapy and Pharmacology},
  year={1984},
  volume={12},
  pages={101-103}
}
A phase-II trial of the second-generation platinum analog 1,2-diaminocyclohexane (4-carboxyphalato) platinum (II) (DACCP) was performed in 33 patients with non-small cell lung cancer. The compound was studied because of its lack of cross resistance in vitro and decreased nephrotoxicity in both preclinical testing and in a phase-I trial. The starting dose… CONTINUE READING